JPRN-UMIN000007071已完成未知
The effect and safety in Telaprevir with combined peginterferon alpha-2b plus ribavirin for chronic hepatitis C patients - Drug adjustment on adverse effect of telaprevir combined therapy (TPR-dose trial)
Department of Hepatology, Osaka City University , Graduate School of Medicine0 个研究点目标入组 100 人开始时间: 2015年12月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
Telaprevir dose adjustment could prevent anemia progression without weakening the anti-viral effect during triple therapy in patients with HCV.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients were excluded women of childbearing potential and pregnancy, lactating women allergic to ribavirin or other nucleoside analogues an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) hemoglobibopathy ( thalassemia, sickle cell disease) severe renal disease or Ccr<50mL/min severe depression or psychosomatic disorders severe liver disease autoimmune hepatitis or HBV drug allergy against interferon
研究者
相似试验
已完成
不适用
Effectiveness and safety of simeprevir-basd triple therapy for chronic hepatitis C in multicenter studyChronic hepatitis CJPRN-UMIN000014568The Kyushu Univerisity Liver Disease Study Group400
终止
不适用
Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapyC Hepatitis, Tri TherapyNCT01716403University Hospital, Grenoble8
终止
3 期
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)InfectionNCT01821963M.D. Anderson Cancer Center1
已完成
不适用
Ribavirin Bioavailability After Telaprevir ExposureHepatitis CNCT02881034Hospices Civils de Lyon37
已完成
1 期
Pharmacokinetic Interactions Between Telaprevir and Un-boosted AtazanavirHepatitis C, ChronicHIV InfectionNCT01818856Hospitales Universitarios Virgen del Rocío14